High-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3

Episode 3 March 16, 2022 00:19:56
High-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3
COR2ED Medical Education
High-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3
/

Show Notes

COR2ED Medical Education: In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin (Associate Attending on the Myeloma Service at the Memorial Sloan Kettering Cancer Center, New York, NY, USA) discuss how they choose the best treatment regimen for patients with multiple myeloma and a high-risk cytogenetic profile. 

Firstly, they discuss the treatment options available for patients with high-risk cytogenetics in the US and in Europe. However, the key question is how to decide, for each individual, which treatment option is the best one. Dr. Mateos and Dr. Lesokhin discuss the factors they consider in these decisions in their clinical practice. Although the prior treatment is the most important consideration in the relapsed setting, the type of cytogenetic abnormality also plays a role. The experts specifically discuss treatment decisions in patients with extramedullary multiple myeloma: a difficult-to-treat population.

The speakers also discuss the future of myeloma treatment. How should trial design be adapted to better meet the needs of patients with a high-risk cytogenetic profile? What will be the role of CAR-T and bispecific antibodies in this population?

The experts conclude by summarising their key take-aways from the discussion.

Other Episodes

Episode 1

June 28, 2022 00:18:42
Episode Cover

PBC Highlights from ILC 2022: Ep. 1

COR2ED Medical Education: In this podcast, Prof. Gideon Hirschfield, Professor of Medicine, Division of Gastroenterology, University of Toronto, Canada and Prof. Ana Lleo, Professor of Internal Medicine, Humanitas University, Milan, Italy, discuss key abstracts on primary biliary cholangitis (PBC) from the International Liver Congress 2022. Their discussions focus on treatments currently available, treatment sequencing, management of adverse events, expected future therapeutic options and how to address the unmet clinical need of this rare liver disease. ...

Listen

Episode 2

July 11, 2022 00:23:31
Episode Cover

Shared decision-making in nmCRPC

Shared decision-making in nmCRPC: Treatment considerations to maintain quality of life COR2ED Medical Education: Brenda Martone, a nurse practitioner at Northwestern Medicine in Chicago Illinois and Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in the United States discuss ‘Shared decision-making in nmCRPC: Treatment considerations to maintain quality of life’ in this GU CONNECT podcast. In this podcast, the experts discuss how patients are more likely to be able to adhere to a treatment plan if they understand their choices and the implications of each treatment.  They discuss how nmCRPC patients are relatively asymptomatic and the importance of understanding the patients’ goals of treatment and how these may differ from a physician’s perspective. Alicia reviews the efficacy and safety data from the key trials for nmCRPC, the SPARTAN trial with apalutamide, the PROSPER trial with enzalutamide and the ARAMIS trial with darolutamide. Brenda discusses ways to manage adverse events for the nmCRPC patients in order to keep them on treatment whilst still maintaining a good quality of life and Alicia explains how she goes about determining the right treatment for the right patient whilst considering comorbidities and drug to drug interactions. ...

Listen

Episode 2

October 21, 2021 00:18:13
Episode Cover

Current and Future Therapeutic Approaches in Colorectal and Gastric Cancer: Immunotherapy - Ep 2

In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer. This second episode focuses on recent developments in immunotherapy approaches in metastatic colorectal and gastric cancer – specifically whether immunotherapy should be used alone, in combination with other treatments or with chemotherapy. Data from several clinical trials are discussed such as KEYNOTE-177, CheckMate 142, CheckMate 649, KEYNOTE 062, and NICHE. The experts also consider the appropriate treatment regimens for MSI-high and MSS colorectal and gastric cancer patients and whether CPS is an appropriate biomarker for gastric cancer. ...

Listen